Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -426.88% is 106% below its 5-year average of -207.15%, near the low end of its 5-year range (-426.88%–16.14%).
205.76% below its 12-month average of -139.62%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -86.93%.
RETURN ON ASSETS (ROA)
-426.88%
RETURN ON ASSETS (ROA) AVG TTM
-139.62%
RETURN ON ASSETS (ROA) AVG 3Y
-270.47%
RETURN ON ASSETS (ROA) AVG 5Y
-207.15%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-205.76%
CURRENT VS 3Y AVG
-57.83%
CURRENT VS 5Y AVG
-106.08%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.01%
median of 600 covered companies
CURRENT VS SECTOR MEDIAN
-1371.75%
vs the sector median at left
Ensysce Biosciences, Inc.
Market Cap
$6.52M
Return on Assets (ROA)
-426.88%
TTM Avg
-139.62%
3Y Avg
-270.47%
5Y Avg
-207.15%
Market Cap
$6.58M
Return on Assets (ROA)
-97.60%
TTM Avg
-274.34%
3Y Avg
-160.93%
5Y Avg
-165.76%
Market Cap
$6.76M
Return on Assets (ROA)
-71.23%
TTM Avg
-61.08%
3Y Avg
-51.04%
5Y Avg
-61.11%
Market Cap
$6.21M
Return on Assets (ROA)
-55.85%
TTM Avg
-69.75%
3Y Avg
-63.38%
5Y Avg
-59.39%
Market Cap
$6.83M
Return on Assets (ROA)
-50.98%
TTM Avg
-191.11%
3Y Avg
-206.10%
5Y Avg
-240.87%
Market Cap
$6.94M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$6.07M
Return on Assets (ROA)
-99.97%
TTM Avg
-120.54%
3Y Avg
-89.96%
5Y Avg
-79.52%
Market Cap
$6.07M
Return on Assets (ROA)
-81.62%
TTM Avg
-81.33%
3Y Avg
-106.24%
5Y Avg
-102.80%
Market Cap
$5.91M
Return on Assets (ROA)
83.82%
TTM Avg
-0.56%
3Y Avg
-31.49%
5Y Avg
-28.41%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | $6.52M | -426.88% | -139.62% | -270.47% | -207.15% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | -97.60% | -274.34% | -160.93% | -165.76% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.76M | -71.23% | -61.08% | -51.04% | -61.11% |
| Biomerica, Inc. (BMRA)vs › | $6.21M | -55.85% | -69.75% | -63.38% | -59.39% |
| Aclarion, Inc. (ACON)vs › | $6.83M | -50.98% | -191.11% | -206.10% | -240.87% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | -283.63% | -124.17% | -74.25% | -35.74% |
| Femasys Inc. (FEMY)vs › | $6.07M | -99.97% | -120.54% | -89.96% | -79.52% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.07M | -81.62% | -81.33% | -106.24% | -102.80% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.91M | 83.82% | -0.56% | -31.49% | -28.41% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.90M | -54.95% | -72.19% | -72.80% | -69.14% |
ROA
-426.9%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -136.54% |
| 2024-12-31 | -142.69% |
| 2023-12-31 | -391.90% |
| 2022-12-31 | -410.74% |
| 2021-12-31 | -177.15% |
| 2020-12-31 | 16.14% |
| 2019-12-31 | -1619.11% |
| 2018-12-31 | -0.66% |
| 2017-12-31 | -0.02% |
